Investor Presentaiton
Innovation: 69 potential new vaccines and medicines
Phase I
2904545* (recombinant protein) + C. difficile
4429016* (bioconjugated, recombinant protein) K. pneumoniae
3993129 (recombinant subunit) CMV1.7
4382276* (mRNA) flu
4396687* (mRNA) COVID-19
4077164* (bivalent GMMA8) INTS9 (Typhimurium + Enteritidis)**
3943104* (recombinant protein)' Therapeutic HSV10
4348413 (GMMA8) Gonorrhea¹
3536867* (bivalent conjugate) Salmonella (Typhoid + Paratyphoid A)
2556286* (Mtb inhibitor) tuberculosis
3186899* (CRK-12 inhibitor) visceral leishmaniasis²
3494245* (proteasome inhibitor) visceral leishmaniasis
3772701 (P falciparum whole cell inhibitor) malaria
3882347* (FimH antagonist) uUTI11
3923868 (P14kẞ inhibitor) viral COPD 12 exacerbations
4182137* (VIR-7832 monoclonal antibody) COVID-191
3965193 (PAPD5/7 inhibitor) HBV13
5251738 (TLR8 agonist) HBV13
3739937 (maturation inhibitor) HIV
cabotegravir (400 mg/ml formulation) HIV
Phase II
3437949* (recombinant protein) 'Malaria fractional dose
4406371 (live, attenuated) MMRV15 new strain
4069327* (bioconjugated, tetravalent) Shigella**
3528869* (viral vector with recombinant protein) Therapeutic HBV1,13
4023393 (conjugated, recombinant protein) MenABCWY 2nd gen 1
4178116 (live, attenuated) Varicella new strain
5101955 (MAPS 16) Pneumococcal 24-Valent - Paediatric
5101956 (MAPS 16) Pneumococcal 24-Valent - Adults
4106647* (protein-adiuvant) + HPV1.17
3036656* (leucyl t-RNA inhibitor) tuberculosis
sanfetrinem cilexetil* (serine beta lactamase inhibitor) tuberculosis
BVL-GSK098* (ethionamide booster) tuberculosis
VIR-2482* (neutralizing monoclonal antibody)^ influenza
3640254 (maturation inhibitor) HIV
3810109* (broadly neutralizing antibody) HIV
4428859* (anti-TIGIT) cancer
Benlysta (anti-BLYS) Systemic sclerosis associated interstitial lung
disease5
4532990 (HSD17B13 siRNA 18) non-alcoholic steatohepatitis³
Phase III/Registration
Bexsero infants US (recombinant protein) MenB19
SKYCovione (SK Bioscience)* COVID-19++
3536819 (conjugated, recombinant protein) MenABCWY 1st gen
3844766* (recombinant protein) RSV 20 older adults
gepotidacin (BTI inhibitor) uUTI11 and GC21
bepirovirsen (HBV13 ASO22) HBV
tebipenem pivoxil* (antibacterial carbapenem) CUT15,23
Xevudy* (sotrovimab/VIR-7831 monoclonal antibody) COVID-19
Blenrep (anti-BCMA ADC14) multiple myeloma
Jemperli (anti-PD-1) 1L endometrial cancer**
Zejula (PARP inhibitor) ovarian, lung and breast cancer
momelotinib* (JAK1, JAK2 and ACVR1 inhibitor) myelofibrosis
cobolimab (anti-TIM-3) NSCLC24
latozinemab* (AL001, anti-sortilin) frontotemporal dementia***
depemokimab (LA 25 anti- IL5) asthma**
Nucala (anti-IL 5) COPD12
daprodustat (HIF-PHI) anaemia of chronic kidney disease
linerixibat (IBAT inhibitor) cholestatic pruritus in primary biliary cholangitis
Infectious Diseases
HIV (VIIV)
Oncology
Immunology/Respiratory
Opportunity Driven
Note: Only the most advanced
indications are shown for each asset.
4004280 (capsid protein inhibitor) HIV
4011499 (capsid protein inhibitor) HIV
4524184* (integrase inhibitor) HIV
3745417 (STING agonist) cancer
4074386* (anti-LAG3) cancer
6097608* (anti-CD96) cancer
4381562* (anti-PVRIG) cancer
XMT-2056*6 (STING agonist ADC14) cancer
(wholly owned by Mersana Therapeutics)
4527226* (AL101, anti-sortilin) neurodegenerative diseases
3858279* (anti-CCL17) osteoarthritis pain
1070806 (anti-IL18) atopic dermatitis
3888130* (anti-IL7) multiple sclerosis
4172239* (DNMT1 inhibitor) - sickle cell disease³
*In-license or other alliance relationship with third party
**Additional indications or candidates also under investigation
++ GSK contributing pandemic adjuvant ^ GSK has exclusive option to co-develop post Phase II 1. In Phase I/II study
+ adjuvanted
2. Transition activities underway to enable further progression by partner 3. Imminent study start 4. Phase III trial in patients with progranulin gene mutation
5. Phase II/III study start expected in 2023 6. GSK has an exclusive global license option to co-develop and commercialise the candidate 7. Cytomegalovirus
8. Generalized Modules for Membrane Antigens 9. Invasive non-typhoidal salmonella 10. Herpes simplex virus 11. Uncomplicated urinary tract infection
12. Chronic obstructive pulmonary disease 13. Hepatitis B virus 14. Antibody drug conjugate 15. Measles, mumps, rubella & varicella
16. Multiple Antigen Presenting System 17. Human papillomavirus 18. Small interfering RNA 19. Meningitis B 20. Respiratory syncytial virus
21. Urogenital gonorrhoea 22. Antisense oligonucleotide 23. Complicated urinary tract infection 24. Non-small cell lung cancer
25. Long-acting
GSK
31View entire presentation